Motilal Oswal's research report on Aurobindo Pharma
Receives approval for Renvela in US : ARBP has received final USFDA approval to manufacture sevelamer carbonate tablet 800mg ( brand nameRenvela; innovator – Genzyme) in the US. Notably, ARBP is the first generic player to receive approval for Renvela , which is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
Outlook
We expect ARBP stock to remain range bound in the near term as the stock has moved up ~50% in less than two months since end- May 20 17. However, the key catalysts in 2HFY18 (including launch of Fondaparinux, Toprol XL, DTG combination, injectable s business ramp -up, and EU business margins improvement ) will help drive growth in the medium term.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
